Clinical Trial: IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer

U.S., July 24 -- ClinicalTrials.gov registry received information related to the study (NCT07722494) titled 'IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer' on July 20.

Brief Summary: This is an open-label, multicenter Phase 3 study to evaluate the safety and tolerability of IBI363 plus bevacizumab in patients with advanced colorectal cancer refractory or intolerant to standard-of-care therapy

Study Start Date: July 20

Study Type: INTERVENTIONAL

Condition: Colorectal Cancer

Intervention: DRUG: IBI363 + bevacizumab

In this arm, patients will receive IBI363 plus bevacizumab

DRUG: Investigator's choice of therapy

In this arm, patients will receive Fruquintinib or Trifluridine and Tipiracil Hydrochloride or Regorafeni...